Know Cancer

forgot password

Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis

Phase 3
18 Years
Not Enrolling
Familial Adenomatous Polyposis

Thank you

Trial Information

Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis

Inclusion Criteria:

- Diagnosis of phenotypic classical FAP with disease involvement of the duodenum and/or

1. Genotype: APC mutation (with or without family history) required

2. Classical FAP Phenotype: 100's to 1,000's of colorectal adenomatous polyps,
usually appearing in teenage years

- UGI endoscopy/LGI endoscopy (proctoscopy/colonoscopy) performed within 30 days of

- Patients with an intact colon/rectum, except for clinical polyposis, and prophylactic
surgery is being considered as a stratification site.

- Rectal/pouch polyposis as a stratification site as follows:

1. At least three years since colectomy with IRA/proctocolectomy with pouch, and
demonstrating polyposis as defined by Stage 1, 2, 3, of the proposed InSiGHT
2011 Staging System (Appendix B) and summarized as follows:

Stage 1: 10-25 polyps, all < 5 mm Stage 2: 10-25 polyps, at least one > 1 cm
Stage 3: >25 polyps amenable to complete removal, or any incompletely removed
sessile polyp, or any evidence of high grade dysplasia, even if completely
removed. [Note: For staging purposes only.]

2. For all subjects, any rectal/pouch polyps > 5 mm must be excised at "baseline".

- Duodenal polyposis as a stratification site; one or more of the following:

1. Current Spigelman Stage 3 or 4. (Refer to Appendix A for Modified Spigelman
Score and Classification table).

2. Prior surgical endoscopic intervention within the past six months for Spigelman
Stage 3 or 4 that may have been down staged to Spigelman 1 or 2.

- Hematopoietic Status (within 30 days prior to randomization):

1. No significant hematologic abnormalities

2. WBC at least 3,000/mm3

3. Platelet count at least 100,000/mm3

4. Hemoglobin at least 10.0 g/dL

5. No history of clinical coagulopathy

- Hepatic Status (within 30 days prior to randomization):

1. Bilirubin no greater than 1.5 times ULN

2. AST and ALT no greater than 1.5 times ULN

3. Alkaline phosphatase no greater than 1.5 times ULN

- Renal Status (within 30 days prior to randomization):

a) Creatinine no greater than 1.5 times ULN

- Hearing:

a) No clinically significant hearing loss, defined in Section 6.2, number 9.

- If female, neither pregnant nor lactating.

- Negative pregnancy test if female of child-bearing potential. Fertile patients must
use effective contraception*.

- Absence of gross blood in stool; red blood on toilet paper only acceptable.

- No discrete gastric or duodenal ulcer greater than 5 mm within the past year except
Helicobacter pylori-related peptic ulcer disease treated with antibiotics.

- No invasive malignancy within the past 5 years except resected non-melanomatous skin
cancer, papillary thyroid cancer, or precancerous cervical dysplasia.

- No other significant medical or psychiatric problems that would preclude study
participation or interfere with capacity to give informed consent.

- Use of 81 mg daily aspirin or 650 mg aspirin not more than once a week are eligible.

- No concurrent warfarin, fluconazole, lithium, Pradaxa® or other direct thrombin
inhibitors, Plavix®, cyclosporine, other NSAIDs (such as ibuprofen, aspirin,
diflunisal), diuretics (furosemide and thiazides), DMSO, methotrexate, probenecid,
propoxyphene hydrochloride, Tylenol® (acetaminophen) preparations containing aspirin
or cytotoxic chemotherapy drugs.

- Willingness to forego concurrent use of supplements containing omega-3 fatty acids,
corticosteroids, non-steroidal anti-inflammatory drugs or other FAP directed drug

- Able to provide informed consent and follow protocol requirements.

Exclusion Criteria:

- Prior pelvic irradiation.

- Patients receiving corticosteroids within 30 days of enrollment.

- Treatment with other investigational agents in the prior 4 weeks.

- Use of other non-steroidal anti-inflammatory drugs (such as ibuprofen) exceeding 4
days per month, in the prior 6 weeks.

- Regular use of aspirin in excess of 650 mg per week.

- Treatment with other FAP directed drug therapy (including sulindac or celecoxib, fish
oil) within 12 weeks of study enrollment.

- Hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or
salicylates; NSAID associated symptoms of gastritis.

- Patients at high cardiovascular disease risk are not eligible for study participation
defined as (a) Clinical diabetes mellitus (Type I or II) requiring glycemic
medications, or; (b)Prior personal history of cardiovascular disease - heart attack,
stroke, transient ischemic attack, or symptomatic peripheral vascular disease, or two
of the following: taking anti-hypertensive medication, taking lipid lowering
medication, and/or current cigarette smoker

- Patients with significant hearing loss are not eligible for study participation
defined as hearing loss that affects everyday life and/or for which a hearing aid is

- Colon/rectum/pouch with high grade dysplasia or cancer on biopsy or a large polyp (>1
cm) not amenable to complete removal.

- Duodenal cancer on biopsy.

- Intra-abdominal desmoid disease, stage III or IV

- Inability to provide informed consent.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Outcome Measure:

Delaying time to the 1st occurrence of any FAP-related event.

Outcome Time Frame:

24 months from the start of treatment

Safety Issue:


Principal Investigator

Carol Burke, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

The Cleveland Clinic


United States: Food and Drug Administration

Study ID:




Start Date:

May 2013

Completion Date:

September 2016

Related Keywords:

  • Familial Adenomatous Polyposis
  • Familial Adenomatous Polyposis
  • Eflornithine
  • Sulindac
  • Adenomatous Polyposis Coli
  • Colorectal Neoplasms
  • Nasopharyngeal Neoplasms



University of Michigan Ann Arbor, Michigan  48109-0624
MD Anderson Cancer Center Houston, Texas  77030-4096
Mayo Clinic Rochester, Minnesota  55905
Cleveland Clinic Cleveland, Ohio  44195
Dana Farber Cancer Institute Boston, Massachusetts  02115
Washington University St. Louis, Missouri  63110